MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells

Eitemau Tebyg

• Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
  gan: Theresa Klümper, et al.
  Cyhoeddwyd: (2020-09-01)
• Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
  gan: Klümper, Theresa, et al.
  Cyhoeddwyd: (2020)
• The role of the lysine histone methylase KMT2D in chronic myeloid leukemia
  gan: Lina Schlemminger, et al.
  Cyhoeddwyd: (2025-09-01)
• The MAP kinase negative regulator DUSP2 (dual specificity phosphatase 2) is controlled by oncogenic microRNA cluster miR-17-92, miR-106a-363 and miR-106b-25
  gan: Victoria Tenhaken, et al.
  Cyhoeddwyd: (2025-06-01)
• Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
  gan: Kaehler, Meike, et al.
  Cyhoeddwyd: (2021)